Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TNX-1200
- Development stage
- Preclinical
- Lead developer
- Tonix Pharmaceuticals
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Percutaneous
01
Overview
TNX-1200 is a live synthesized vaccinia virus vaccine candidate being developed by Tonix Pharmaceuticals in collaboration with the University of Alberta. Utilizing synthetic biology techniques, the vaccine was synthesized by Professor David Evans and Dr. Ryan Noyce to serve as a potential medical countermeasure for the prevention and treatment of smallpox and monkeypox. TNX-1200 represents a synthetic version of the vaccinia virus, which has a long history of use in smallpox immunization programs. It is distinct from Tonix's other orthopoxvirus vaccine candidate, TNX-801, which is based on a synthetic horsepox virus.
Beyond the preview
Go deeper on TNX-1200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TNX-1200.